全文获取类型
收费全文 | 117902篇 |
免费 | 9837篇 |
国内免费 | 6753篇 |
专业分类
耳鼻咽喉 | 1111篇 |
儿科学 | 1999篇 |
妇产科学 | 1013篇 |
基础医学 | 11536篇 |
口腔科学 | 2047篇 |
临床医学 | 14761篇 |
内科学 | 14821篇 |
皮肤病学 | 1690篇 |
神经病学 | 4900篇 |
特种医学 | 4458篇 |
外国民族医学 | 26篇 |
外科学 | 10379篇 |
综合类 | 24536篇 |
现状与发展 | 23篇 |
一般理论 | 7篇 |
预防医学 | 11202篇 |
眼科学 | 2451篇 |
药学 | 12761篇 |
96篇 | |
中国医学 | 7306篇 |
肿瘤学 | 7369篇 |
出版年
2024年 | 274篇 |
2023年 | 1063篇 |
2022年 | 2825篇 |
2021年 | 3842篇 |
2020年 | 3047篇 |
2019年 | 2482篇 |
2018年 | 2631篇 |
2017年 | 2935篇 |
2016年 | 2919篇 |
2015年 | 4670篇 |
2014年 | 6077篇 |
2013年 | 6831篇 |
2012年 | 9823篇 |
2011年 | 10423篇 |
2010年 | 8272篇 |
2009年 | 7261篇 |
2008年 | 8277篇 |
2007年 | 8178篇 |
2006年 | 7645篇 |
2005年 | 6724篇 |
2004年 | 5269篇 |
2003年 | 5276篇 |
2002年 | 4167篇 |
2001年 | 3325篇 |
2000年 | 2592篇 |
1999年 | 1666篇 |
1998年 | 903篇 |
1997年 | 947篇 |
1996年 | 636篇 |
1995年 | 548篇 |
1994年 | 474篇 |
1993年 | 313篇 |
1992年 | 351篇 |
1991年 | 292篇 |
1990年 | 256篇 |
1989年 | 209篇 |
1988年 | 178篇 |
1987年 | 160篇 |
1986年 | 121篇 |
1985年 | 121篇 |
1984年 | 72篇 |
1983年 | 56篇 |
1982年 | 41篇 |
1981年 | 30篇 |
1980年 | 20篇 |
1979年 | 37篇 |
1978年 | 34篇 |
1976年 | 23篇 |
1973年 | 27篇 |
1970年 | 20篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
立体定向开放显微手术治疗脑内致痫小病灶 总被引:1,自引:1,他引:0
查 《中华神经外科疾病研究杂志》2006,5(1):64-66
目的脑内致癫痫小病灶术前、术中的精确定位和病灶切除,是手术治疗效果的关键。探讨立体定向开放微创手术,皮层电极监测下切除脑内致痫小病灶的手术方法。方法53例症状性癫痫病例,CT、MR I检查有脑内小病灶(直径在0.5~3.0 cm),24 h视频脑电图确认致痫灶为脑内单发病灶。ASA 601S型立体定向仪CT引导辅助全麻环钻开颅,导针穿刺放置导管引导,显微镜下手术分离、切除病灶,皮层脑电图确认将致痫灶切除。结果病灶全切率达96.2%,术后50例得到随访,随访时间5~12个月,平均6.3个月,癫痫消失45例,脑电图检查记录到癫痫波11例,临床癫痫发作5例。因肺癌死亡3例。结论CT立体定向引导,显微手术切除颅内致痫小病灶,术中皮层电极确认将致痫灶切除,是一种定位精确、微创、安全、有效的治疗方法。 相似文献
92.
目的:临床观察QuickWhite美白胶对氟斑牙患者的漂白治疗效果。方法:选取63例I ̄III级不同程度的氟斑牙患者,采用QuickWhite美白胶进行漂白治疗,分别于治疗前及治疗后用Vita比色板对牙齿比色并记录,评价治疗效果。评价标准:治疗后无改变为无效,变白2个色阶为有效,变白3个色阶以上为显效。结果:使用QuickWhite美白胶治疗后,I级患者显效率为95.6%,II级患者显效率为50%。结论:QuickWhite美白胶可为氟斑牙患者提供可靠的漂白治疗效果。 相似文献
93.
表皮生长因子及其受体与流产关系的探讨 总被引:4,自引:0,他引:4
采用放射免疫竞争抑制饱和分析法,检测47例难免流产患者,65例人工流产及20例健康非孕妇女血清表皮生长因子(EGF)水平;同时采用免疫组织化学法检测流产者胚胎组织中表皮生长因子受体(EGFR)表达程度。结果:人工流产组血清EGF水平高于自然流产及非孕妇女,而自然流产与非孕妇女差异无显著性;胚胎组织中EGFR阳性表达率人工流产组明显高于自然流产组。提示:EGF通过与其受体结合对妊娠维持、胚胎及胎儿的 相似文献
94.
The rat lung and nasal cavity are two target organs for carcinogenesis by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). In order to characterize further the enzymes involved in the bioactivation of NNK, detailed kinetic and inhibitory studies were conducted with rat lung and nasal mucosa microsomes, and the results were compared with previous studies. The enzymes in rat lung microsomes catalyzed the alpha-hydroxylation, pyridine N-oxidation and carbonyl reduction of NNK. The apparent Km for the formation of the NNK-derived keto aldehyde, NNK-N-oxide, the NNK-derived keto alcohol and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol were 28.8, 10.4, 7.0 and 178.1 microM respectively. In rat nasal microsomes, alpha-hydroxylation was the predominant pathway and the rate was approximately 200 times higher than that in lung microsomes. The apparent Kms for keto aldehyde and keto alcohol formation in rat nasal microsomes were 9.6 and 10.1 microM respectively. The cytochrome P450 inhibitors metyrapone and carbon monoxide markedly inhibited the metabolism of NNK in both rat lung and nasal microsomes. In rat lung microsomes, alpha-naphthoflavone and monospecific antibodies against P450s 1A2, 2A1 and 2B1 inhibited the formation of keto aldehyde by 39, 46, 64 and 23% respectively. In rat nasal microsomes, alpha-naphthoflavone and antibodies against P450s 1A2, 2A1 and 3A inhibited the metabolism of NNK by 80, 35, 20 and 14% respectively. The results indicate that cytochromes P450 play a major role in the metabolic activation of NNK in rat lung and nasal microsomes, and that there are tissue-related differences in NNK metabolism. 相似文献
95.
小切口胆囊切除术108例临床观察 总被引:1,自引:0,他引:1
本文报告腹部切口5-8cm的小切口胆囊切除术108例,与同期大切口胆囊切除术相比,具有创伤较小、恢复较快、并发症少、切口疤痕小的优点,虽不如腹腔镜胆囊切除术(LC)的疼痛轻、恢复快,但并症比LC少,只要适应症选择得当,在术者的经验和技术较成熟的情况下,不昔为一种可供选择的方法。 相似文献
96.
Zheng Qi-xin Zhu Tong-bai Du Jing-yuan Hong Guang-xiang Li Shi-pu Yan Yun-hua Zhang En-dang 《华中科技大学学报(医学英德文版)》1992,12(3):173-178
Summary The authors have prepared the artificial bone of porous tricalcium phosphate ceramics according to an appropriate formula
and manufacturing technology. Physical and chemical testing shows that it possesses several distinguishing features: the communicating
pores and macro/micropores; mean pore size, 380 μm (from 240 μm to 510 μm); porosity, 46.4 %; and compressive strength, 97.4
kg/cm2. It consists of CaO (49.09 %) and P2O5 (48.84 %). The testing of its biocompatibility shows that it is devoid of systemic or local toxicity, and free of irritation
or foreign body response in tissues, and it does not result in hemolysis or mutation. The new bone readily grows into its
pores with direct contact to the implanted material. 11 cases of bone defects were treated with this artificial bone with
satisfactory results. 相似文献
97.
C L Yu C Y Tsai S Y Hong C S Lue C C Chiu B N Chiang S H Han S R Wang 《Scandinavian journal of rheumatology》1991,20(1):8-15
Extracellular phospholipase A2 (PLA2) is a proinflammatory enzyme found especially in the inflammatory exudate to modulate blood flow to areas of antigen stimulation. In this study we found that PLA2 exerted a biphasic effect on the proliferation of phytohemagglutinin (PHA)-stimulated human mononuclear cells (PHA MNC). At low concentrations range from 0.001 to 1 U/ml, PLA2 enhanced the proliferation of PHA MNC (maximal increase was 37.0 +/- 5.67%). Conversely, at concentrations over 10 U/ml, PLA2 markedly suppressed the PHA-induced MNC proliferation (maximal decrease was 88.86 +/- 2.89%). PLA2 was non-toxic to lymphocytes after three days culture, unless the concentration was higher than 100 U/ml. The membrane polarization of PHA-stimulated lymphocytes was also increased by PLA2 at a low concentration. In addition, PLA2 displayed a similar effect on the proliferation of streptokinase-streptodornase (SK/SD) or allogeneic cell stimulated lymphocytes. The change of lymphocyte proliferation by PLA2, was parallel to the change of percentage of helper T cells. Furthermore--a CD4-rich population was proved more susceptible to PLA2 effect than a CD8-rich population. Para-bromophenacyl bromide (pBPB), an irreversible inhibitor of PLA2, abrogated the biphasic effect of PLA2 on PHA MNC proliferation. These results suggest that PLA2 plays a regulatory role on immune reactions by modulating the percentage of helper T cells. 相似文献
98.
99.
六味地黄汤对实验性糖尿病大鼠心、肝、肾组织中过氧化氢酶活性和过氧化脂质含量的影响 总被引:7,自引:0,他引:7
用四氧嘧啶诱导雄性Wistar大鼠为模型进行研究.结果发现,四氧嘧啶大鼠血糖明显升高,且心、肝、肾组织中过氧化氢酶活性较正常组明显降低,过氧化脂质含量在心、肝组织中明显增高,过氧化脂质与过氧化氢酶比值在心、肝、肾组织中均明显高于正常组,表明糖尿病状态下大鼠心、肝、肾组织中均自由基生成增多,氧化损伤加重.经六味地黄汤治疗后,血糖明显下降,但心、肝、肾组织中的过氧化氢酶活性无改变;而心肌中过氧化脂质含量和过氧化脂质与过氧化氢酶比值则明显降低,过氧化脂质含量和过氧化脂质与过氧化氢酶比值在肝、肾组织中无变化,表明六味地黄汤能明显清除心肌中自由基,抑制心肌中脂质过氧化,且此作用并不是通过提高过氧化氢酶活性来达到. 相似文献
100.
Jin S. Lee Herman I. Libshitz William K. Murphy Diane Jeffries Waun K. Hong 《Investigational new drugs》1990,8(3):299-304
Summary Thirty-one patients with stage IIIB or IV non-small cell lung cancer (NSCLC) were treated with intravenous 10-EdAM on a weekly basis. The starting dose was 80 mg/m2, with subsequent doses adjusted depending on evidence of toxicity. There were 20 men and 11 women with a median age of 58 years (range, 33–75). Response was evaluated in 30 patients, 5 with evaluable but not measurable tumors and 25 with measurable indicator lesions. There were no complete remissions; 3 patients achieved partial remission. Nine patients had a minor response, 6 showed no change, and 12 had progressive disease. Median survival for all 31 patients was 43 weeks (range, 12–65+). During the first 3-week period, the 10-EdAM dose was reduced or withheld in 19 patients (because of stomatitis in 12, SGPT elevation in 3, skin rash in 2, and granulocytopenia in 2), escalated in 11 patients, and unchanged in 1 patient. A mean of 34–88 mg/m2of 10-EdAM (median, 50) was given per week during the first 5-week period. Myelotoxicity was infrequent and there was no significant nephrotoxicity. Considering the modest side effects of this treatment and the conservative dose-modification schedule which mandated substantial dose reductions, we conclude that 10-EdAM is a promising antitumor agent for NSCLC. 相似文献